Dicerna Pharmaceuticals, Inc. (DRNA)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.20+0.46 (+9.70%)
At close: 4:00 PM EDT
People also watch:
CNCEGNCAQUREEPZMAKBA
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open4.81
Prev Close4.74
Bid3.12 x 300
Ask5.80 x 200
Day's Range4.77 - 5.80
52wk Range2.69 - 15.93
1y Target EstN/A
Market Cap107.92M
P/E Ratio (ttm)-1.75
BetaN/A
Volume1,226,672
Avg Vol (3m)247,254
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Business Wire4 days ago

    Dicerna Prioritizes Resources to Advance GalXC™ Product Candidates

    Dicerna Pharmaceuticals, Inc. , a leading developer of investigational RNA interference therapeutics, today announced that the Company will focus its resources on its proprietary GalXCTM technology platform to advance development of product candidates in its core therapeutic areas of rare diseases, chronic liver diseases, cardiovascular disease and viral infectious diseases.

  • Dicerna Pharmaceuticals (DRNA) Worth a Look: Stock Up 6%
    Zacks8 days ago

    Dicerna Pharmaceuticals (DRNA) Worth a Look: Stock Up 6%

    Dicerna Pharmaceuticals, Inc. (DRNA) was a big mover last session, as the company saw its shares rise nearly 6% on the day.

  • Dicerna Pharmaceuticals, Inc. :DRNA-US: Earnings Analysis: Q2, 2016 By the Numbers : September 21, 2016
    Capital Cube9 days ago

    Dicerna Pharmaceuticals, Inc. :DRNA-US: Earnings Analysis: Q2, 2016 By the Numbers : September 21, 2016

    Categories: Yahoo Finance Get free summary analysis Dicerna Pharmaceuticals, Inc. reports financial results for the quarter ended June 30, 2016. Analysis Summary numbers: Revenues of USD 0 million, Net Earnings of USD -15.62 million. The company does not seem to have a viable operating strategy as is evident from low net profit margins (currently -34,151.63% vs. peer median ... Read more (Read more...)